# David J Gordon

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8057441/publications.pdf

Version: 2024-02-01

| | | | |
|---|---|---|---|
| 32 papers | 2,505 citations | 430442 18 h-index | 433756 31 g-index |
| 32 all docs | 32 docs citations | 32 times ranked | 3963 citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | Oncogenic RABL6A promotes NF1-associated MPNST progression in vivo. Neuro-Oncology Advances, 2022, 4, vdac047. | 0.4 | 3 |
| 2 | Disruption of dNTP homeostasis by ribonucleotide reductase hyperactivation overcomes AML differentiation blockade. Blood, 2022, 139, 3752-3770. | 0.6 | 12 |
| 3 | Inhibitor of DNA binding 2 (ID2) regulates the expression of developmental genes and tumorigenesis in ewing sarcoma. Oncogene, 2022, 41, 2873-2884. | 2.6 | 2 |
| 4 | The translational repressor 4E-BP1 regulates RRM2 levels and functions as a tumor suppressor in Ewing sarcoma tumors. Oncogene, 2021, 40, 564-577. | 2.6 | 13 |
| 5 | Combination therapies for MPNSTs targeting RABL6A-RB1 signaling. Oncotarget, 2021, 12, 10-14. | 0.8 | 5 |
| 6 | Preclinical efficacy of prexasertib in acute lymphoblastic leukemia. British Journal of Haematology, 2021, 194, 1094-1098. | 1.2 | 1 |
| 7 | Inhibition of the ATRâ€“CHK1 Pathway in Ewing Sarcoma Cells Causes DNA Damage and Apoptosis via the CDK2-Mediated Degradation of RRM2. Molecular Cancer Research, 2020, 18, 91-104. | 1.5 | 43 |
| 8 | Eltrombopag inhibits the proliferation of Ewing sarcoma cells via iron chelation and impaired DNA replication. BMC Cancer, 2020, 20, 1171. | 1.1 | 7 |
| 9 | CDKs in Sarcoma: Mediators of Disease and Emerging Therapeutic Targets. International Journal of Molecular Sciences, 2020, 21, 3018. | 1.8 | 30 |
| 10 | Pharmacologic Ascorbate Primes Pancreatic Cancer Cells for Death by Rewiring Cellular Energetics and Inducing DNA Damage. Molecular Cancer Research, 2019, 17, 2102-2114. | 1.5 | 21 |
| 11 | SN-38 Conjugated Gold Nanoparticles Activated by Ewing Sarcoma Specific mRNAs Exhibit In Vitro and In Vivo Efficacy. Bioconjugate Chemistry, 2018, 29, 1111-1118. | 1.8 | 16 |
| 12 | mTORC1/2 and Protein Translation Regulate Levels of CHK1 and the Sensitivity to CHK1 Inhibitors in Ewing Sarcoma Cells. Molecular Cancer Therapeutics, 2018, 17, 2676-2688. | 1.9 | 27 |
| 13 | Development of Secondary Acute Myeloid Leukemia in a Pediatric Patient Concurrently Receiving Primary Therapy for Ewing Sarcoma. Journal of Pediatric Hematology/Oncology, 2017, 39, e370-e372. | 0.3 | 4 |
| 14 | Inhibition of CHK1 sensitizes Ewing sarcoma cells to the ribonucleotide reductase inhibitor gemcitabine. Oncotarget, 2017, 8, 87016-87032. | 0.8 | 23 |
| 15 | Modeling the initiation of Ewing sarcoma tumorigenesis in differentiating human embryonic stem cells. Oncogene, 2016, 35, 3092-3102. | 2.6 | 20 |
| 16 | Gene expression signature based screening identifies ribonucleotide reductase as a candidate therapeutic target in Ewing sarcoma. Oncotarget, 2016, 7, 63003-63019. | 0.8 | 31 |
| 17 | Drug conjugated nanoparticles activated by cancer cell specific mRNA. Oncotarget, 2016, 7, 38243-38256. | 0.8 | 17 |
| 18 | Aurea Mediocritas: The Importance of a Balanced Genome. Cold Spring Harbor Perspectives in Biology, 2014, 6, a015842-a015842. | 2.3 | 19 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | Causes and consequences of aneuploidy in cancer. Nature Reviews Genetics, 2012, 13, 189-203. | 7.7 | 700 |
| 20 | A pediatric case series of acute hemolysis after administration of intravenous immunoglobulin. American Journal of Hematology, 2009, 84, 771-772. | 2.0 | 24 |
| 21 | Peptideâ€Based Inhibitors of Amyloid Assembly. Methods in Enzymology, 2006, 413, 273-312. | 0.4 | 126 |
| 22 | Spatial Separation of Î²-Sheet Domains of Î²-Amyloid:Â Disruption of Each Î²-Sheet byN-Methyl Amino Acidsâ€. Biochemistry, 2006, 45, 9485-9495. | 1.2 | 42 |
| 23 | AÎ²40-Lactam(D23/K28) Models a Conformation Highly Favorable for Nucleation of Amyloid. Biochemistry, 2005, 44, 6003-6014. | 1.2 | 241 |
| 24 | Increasing the Amphiphilicity of an Amyloidogenic Peptide Changes the Î²-Sheet Structure in the Fibrils from Antiparallel to Parallel. Biophysical Journal, 2004, 86, 428-434. | 0.2 | 119 |
| 25 | Probing the Role of Backbone Hydrogen Bonding in Î²-Amyloid Fibrils with Inhibitor Peptides Containing Ester Bonds at Alternate Positions. Biochemistry, 2003, 42, 475-485. | 1.2 | 108 |
| 26 | Structure of Spin-Labeled Methylmethanethiolsulfonate in Solution and Bound to TEM-1 Î²-Lactamase Determined by Electron Nuclear Double Resonance Spectroscopyâ€. Biochemistry, 2002, 41, 797-808. | 1.2 | 7 |
| 27 | Gas-Phase Photochemistry of the Photoactive Yellow Protein Chromophoretrans-p-Coumaric Acid. Journal of the American Chemical Society, 2002, 124, 6194-6201. | 6.6 | 71 |
| 28 | Supramolecular Structure in Full-Length Alzheimer's Î²-Amyloid Fibrils: Evidence for a Parallel Î²-Sheet Organization from Solid-State Nuclear Magnetic Resonance. Biophysical Journal, 2002, 83, 1205-1216. | 0.2 | 309 |
| 29 | Inhibition of Î²-Amyloid(40) Fibrillogenesis and Disassembly of Î²-Amyloid(40) Fibrils by Short Î²-Amyloid Congeners ContainingN-Methyl Amino Acids at Alternate Residuesâ€. Biochemistry, 2001, 40, 8237-8245. | 1.2 | 257 |
| 30 | pH dependent self assembly of Î²-amyloid(10-35) and Î²-amyloid(10-35)-PEG3000. Journal of Applied Crystallography, 2000, 33, 535-539. | 1.9 | 43 |
| 31 | Familial British Dementia: Expression and Metabolism of BRI. Annals of the New York Academy of Sciences, 2000, 920, 93-99. | 1.8 | 18 |
| 32 | Furin mediates enhanced production of fibrillogenic ABri peptides in familial British dementia. Nature Neuroscience, 1999, 2, 984-988. | 7.1 | 146 |